Ramírez-Farías, C.; Ventura-Juárez, J.; Calvillo-Robledo, A.; Ávila-Blanco, M.E.; González-Blas, D.; Correa-Basurto, J.; Quintanar Stephano, A.
N-(2-Hydroxyphenyl)-2-Propylpentanamide Modulates HDAC1 and GPER1 Expression in a Rodent Model of Triple-Negative Breast Cancer. Biomedicines 2026, 14, 322.
https://doi.org/10.3390/biomedicines14020322
AMA Style
Ramírez-Farías C, Ventura-Juárez J, Calvillo-Robledo A, Ávila-Blanco ME, González-Blas D, Correa-Basurto J, Quintanar Stephano A.
N-(2-Hydroxyphenyl)-2-Propylpentanamide Modulates HDAC1 and GPER1 Expression in a Rodent Model of Triple-Negative Breast Cancer. Biomedicines. 2026; 14(2):322.
https://doi.org/10.3390/biomedicines14020322
Chicago/Turabian Style
Ramírez-Farías, Cynthia, Javier Ventura-Juárez, Argelia Calvillo-Robledo, Manuel Enrique Ávila-Blanco, Daniel González-Blas, José Correa-Basurto, and Andrés Quintanar Stephano.
2026. "N-(2-Hydroxyphenyl)-2-Propylpentanamide Modulates HDAC1 and GPER1 Expression in a Rodent Model of Triple-Negative Breast Cancer" Biomedicines 14, no. 2: 322.
https://doi.org/10.3390/biomedicines14020322
APA Style
Ramírez-Farías, C., Ventura-Juárez, J., Calvillo-Robledo, A., Ávila-Blanco, M. E., González-Blas, D., Correa-Basurto, J., & Quintanar Stephano, A.
(2026). N-(2-Hydroxyphenyl)-2-Propylpentanamide Modulates HDAC1 and GPER1 Expression in a Rodent Model of Triple-Negative Breast Cancer. Biomedicines, 14(2), 322.
https://doi.org/10.3390/biomedicines14020322
